Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells
Aging increases the risks for developing fibrocontractile membranes on the retina, which causes significant macular distortion, as in the idiopathic epiretinal membrane (iERM). Retinal Müller glial cells are components of these membranes and may play a key role in the iERM pathogenesis. The transfor...
Gespeichert in:
Veröffentlicht in: | Experimental eye research 2023-01, Vol.226, p.109336-109336, Article 109336 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 109336 |
---|---|
container_issue | |
container_start_page | 109336 |
container_title | Experimental eye research |
container_volume | 226 |
creator | da Silva, Rafael André Roda, Vinicius Moraes de Paiva Akamine, Priscilla Sayami da Silva, Daniela Simões Siqueira, Paula Veloso Matsuda, Monique Hamassaki, Dânia Emi |
description | Aging increases the risks for developing fibrocontractile membranes on the retina, which causes significant macular distortion, as in the idiopathic epiretinal membrane (iERM). Retinal Müller glial cells are components of these membranes and may play a key role in the iERM pathogenesis. The transforming growth factor-β (TGF-β) induces Müller cell transdifferentiation into myofibroblast, reducing glial cell markers (glutamine synthetase, GS, and glial fibrillary acidic protein, GFAP) and increasing α-smooth muscle actin (α-SMA). Our aim was to investigate the effect of the TGF-β inhibitor galunisertib (LY2157299) on the glial-mesenchymal transition and contraction of Müller cells.
MIO-M1 human Müller cells were treated with TGF-β1 (10 ng/mL), galunisertib (5, 10 and 20 μM) and TGF-β1+galunisertib for 24h and 48h. Galunisertib cytotoxicity was analyzed by MTT and trypan blue, and TGF-β1 blockade by phospho-SMAD3 immunofluorescence. Caspase-3 (cell death indicator), GS, GFAP and α-SMA expression was examined by immunofluorescence, Western blotting, and qPCR analysis. Cell contractility was determined by collagen gel contraction assay with Müller cells incorporated.
Galunisertib did not show cytotoxicity at the concentrations evaluated and maintained the Müller cells phenotype, ensuring the GS expression. Galunisertib inhibited the TGF-β1 pathway by decreasing phospho-SMAD3 immunoreactivity, attenuated the α-SMA expression, and prevented the contraction of Müller cells in collagen gel.
Although more studies are needed, in vitro assays suggest that galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes and prevent retinal detachment and consequent loss of vision.
•TGF-β signaling induces glial-mesenchymal transition.•Galunisertib inhibits TGF-β-induced glial-mesenchymal transition and Müller cell contraction.•Galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes. |
doi_str_mv | 10.1016/j.exer.2022.109336 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2746391182</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014483522004171</els_id><sourcerecordid>2746391182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c271t-da88d2d8834dca5c7cc666d2c2fb307fbf8c77c49d98a01782d695879b65823d3</originalsourceid><addsrcrecordid>eNp9kL1uFDEURi0EIsvCC6RALmlm8c-M7ZFoQkQCUlCapLY89p2sN56Zje0F9rVSp6PnmeJlAmWqa12d79P1QeiYkhUlVHzcrOAXxBUjjJVFy7l4gRblISpCiHyJFoTQuqoVb47Qm5Q2ZctrWb9GR1zUTSNks0DT5zDZW-MATz3Oa8BX52fVn3u8NXn90-xxt8c3JuxGnyBm32E_rn3nc_rL3gRvQjVAgtGu94MJOEczJp_9NBYSf__9EALEmcMWQkhv0avehATvnuYSXZ99uTr9Wl1cnn87PbmoLJM0V84o5ZhTitfOmsZKa4UQjlnWd5zIvuuVldLWrWuVIVQq5kTbKNl2olGMO75EH-bebZzudpCyHnw6XGBGmHZJM1kL3lJa4CViM2rjlFKEXm-jH0zca0r0QbTe6INofRCtZ9El9P6pf9cN4P5H_pktwKcZgPLLH77Ek_XFEzgfwWbtJv9c_yOkM5FQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2746391182</pqid></control><display><type>article</type><title>Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>da Silva, Rafael André ; Roda, Vinicius Moraes de Paiva ; Akamine, Priscilla Sayami ; da Silva, Daniela Simões ; Siqueira, Paula Veloso ; Matsuda, Monique ; Hamassaki, Dânia Emi</creator><creatorcontrib>da Silva, Rafael André ; Roda, Vinicius Moraes de Paiva ; Akamine, Priscilla Sayami ; da Silva, Daniela Simões ; Siqueira, Paula Veloso ; Matsuda, Monique ; Hamassaki, Dânia Emi</creatorcontrib><description>Aging increases the risks for developing fibrocontractile membranes on the retina, which causes significant macular distortion, as in the idiopathic epiretinal membrane (iERM). Retinal Müller glial cells are components of these membranes and may play a key role in the iERM pathogenesis. The transforming growth factor-β (TGF-β) induces Müller cell transdifferentiation into myofibroblast, reducing glial cell markers (glutamine synthetase, GS, and glial fibrillary acidic protein, GFAP) and increasing α-smooth muscle actin (α-SMA). Our aim was to investigate the effect of the TGF-β inhibitor galunisertib (LY2157299) on the glial-mesenchymal transition and contraction of Müller cells.
MIO-M1 human Müller cells were treated with TGF-β1 (10 ng/mL), galunisertib (5, 10 and 20 μM) and TGF-β1+galunisertib for 24h and 48h. Galunisertib cytotoxicity was analyzed by MTT and trypan blue, and TGF-β1 blockade by phospho-SMAD3 immunofluorescence. Caspase-3 (cell death indicator), GS, GFAP and α-SMA expression was examined by immunofluorescence, Western blotting, and qPCR analysis. Cell contractility was determined by collagen gel contraction assay with Müller cells incorporated.
Galunisertib did not show cytotoxicity at the concentrations evaluated and maintained the Müller cells phenotype, ensuring the GS expression. Galunisertib inhibited the TGF-β1 pathway by decreasing phospho-SMAD3 immunoreactivity, attenuated the α-SMA expression, and prevented the contraction of Müller cells in collagen gel.
Although more studies are needed, in vitro assays suggest that galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes and prevent retinal detachment and consequent loss of vision.
•TGF-β signaling induces glial-mesenchymal transition.•Galunisertib inhibits TGF-β-induced glial-mesenchymal transition and Müller cell contraction.•Galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes.</description><identifier>ISSN: 0014-4835</identifier><identifier>EISSN: 1096-0007</identifier><identifier>DOI: 10.1016/j.exer.2022.109336</identifier><identifier>PMID: 36455675</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Actins - metabolism ; Collagen - metabolism ; Ependymoglial Cells - metabolism ; Epiretinal Membrane - metabolism ; Galunisertib ; Glial-mesenchymal transition ; Humans ; Müller cell ; Neuroglia - metabolism ; TGF-β ; Transforming Growth Factor beta - metabolism ; Transforming Growth Factor beta1 - metabolism ; Transforming Growth Factor beta1 - pharmacology</subject><ispartof>Experimental eye research, 2023-01, Vol.226, p.109336-109336, Article 109336</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c271t-da88d2d8834dca5c7cc666d2c2fb307fbf8c77c49d98a01782d695879b65823d3</citedby><cites>FETCH-LOGICAL-c271t-da88d2d8834dca5c7cc666d2c2fb307fbf8c77c49d98a01782d695879b65823d3</cites><orcidid>0000-0002-4351-6002</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.exer.2022.109336$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36455675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>da Silva, Rafael André</creatorcontrib><creatorcontrib>Roda, Vinicius Moraes de Paiva</creatorcontrib><creatorcontrib>Akamine, Priscilla Sayami</creatorcontrib><creatorcontrib>da Silva, Daniela Simões</creatorcontrib><creatorcontrib>Siqueira, Paula Veloso</creatorcontrib><creatorcontrib>Matsuda, Monique</creatorcontrib><creatorcontrib>Hamassaki, Dânia Emi</creatorcontrib><title>Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells</title><title>Experimental eye research</title><addtitle>Exp Eye Res</addtitle><description>Aging increases the risks for developing fibrocontractile membranes on the retina, which causes significant macular distortion, as in the idiopathic epiretinal membrane (iERM). Retinal Müller glial cells are components of these membranes and may play a key role in the iERM pathogenesis. The transforming growth factor-β (TGF-β) induces Müller cell transdifferentiation into myofibroblast, reducing glial cell markers (glutamine synthetase, GS, and glial fibrillary acidic protein, GFAP) and increasing α-smooth muscle actin (α-SMA). Our aim was to investigate the effect of the TGF-β inhibitor galunisertib (LY2157299) on the glial-mesenchymal transition and contraction of Müller cells.
MIO-M1 human Müller cells were treated with TGF-β1 (10 ng/mL), galunisertib (5, 10 and 20 μM) and TGF-β1+galunisertib for 24h and 48h. Galunisertib cytotoxicity was analyzed by MTT and trypan blue, and TGF-β1 blockade by phospho-SMAD3 immunofluorescence. Caspase-3 (cell death indicator), GS, GFAP and α-SMA expression was examined by immunofluorescence, Western blotting, and qPCR analysis. Cell contractility was determined by collagen gel contraction assay with Müller cells incorporated.
Galunisertib did not show cytotoxicity at the concentrations evaluated and maintained the Müller cells phenotype, ensuring the GS expression. Galunisertib inhibited the TGF-β1 pathway by decreasing phospho-SMAD3 immunoreactivity, attenuated the α-SMA expression, and prevented the contraction of Müller cells in collagen gel.
Although more studies are needed, in vitro assays suggest that galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes and prevent retinal detachment and consequent loss of vision.
•TGF-β signaling induces glial-mesenchymal transition.•Galunisertib inhibits TGF-β-induced glial-mesenchymal transition and Müller cell contraction.•Galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes.</description><subject>Actins - metabolism</subject><subject>Collagen - metabolism</subject><subject>Ependymoglial Cells - metabolism</subject><subject>Epiretinal Membrane - metabolism</subject><subject>Galunisertib</subject><subject>Glial-mesenchymal transition</subject><subject>Humans</subject><subject>Müller cell</subject><subject>Neuroglia - metabolism</subject><subject>TGF-β</subject><subject>Transforming Growth Factor beta - metabolism</subject><subject>Transforming Growth Factor beta1 - metabolism</subject><subject>Transforming Growth Factor beta1 - pharmacology</subject><issn>0014-4835</issn><issn>1096-0007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kL1uFDEURi0EIsvCC6RALmlm8c-M7ZFoQkQCUlCapLY89p2sN56Zje0F9rVSp6PnmeJlAmWqa12d79P1QeiYkhUlVHzcrOAXxBUjjJVFy7l4gRblISpCiHyJFoTQuqoVb47Qm5Q2ZctrWb9GR1zUTSNks0DT5zDZW-MATz3Oa8BX52fVn3u8NXn90-xxt8c3JuxGnyBm32E_rn3nc_rL3gRvQjVAgtGu94MJOEczJp_9NBYSf__9EALEmcMWQkhv0avehATvnuYSXZ99uTr9Wl1cnn87PbmoLJM0V84o5ZhTitfOmsZKa4UQjlnWd5zIvuuVldLWrWuVIVQq5kTbKNl2olGMO75EH-bebZzudpCyHnw6XGBGmHZJM1kL3lJa4CViM2rjlFKEXm-jH0zca0r0QbTe6INofRCtZ9El9P6pf9cN4P5H_pktwKcZgPLLH77Ek_XFEzgfwWbtJv9c_yOkM5FQ</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>da Silva, Rafael André</creator><creator>Roda, Vinicius Moraes de Paiva</creator><creator>Akamine, Priscilla Sayami</creator><creator>da Silva, Daniela Simões</creator><creator>Siqueira, Paula Veloso</creator><creator>Matsuda, Monique</creator><creator>Hamassaki, Dânia Emi</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4351-6002</orcidid></search><sort><creationdate>202301</creationdate><title>Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells</title><author>da Silva, Rafael André ; Roda, Vinicius Moraes de Paiva ; Akamine, Priscilla Sayami ; da Silva, Daniela Simões ; Siqueira, Paula Veloso ; Matsuda, Monique ; Hamassaki, Dânia Emi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c271t-da88d2d8834dca5c7cc666d2c2fb307fbf8c77c49d98a01782d695879b65823d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Actins - metabolism</topic><topic>Collagen - metabolism</topic><topic>Ependymoglial Cells - metabolism</topic><topic>Epiretinal Membrane - metabolism</topic><topic>Galunisertib</topic><topic>Glial-mesenchymal transition</topic><topic>Humans</topic><topic>Müller cell</topic><topic>Neuroglia - metabolism</topic><topic>TGF-β</topic><topic>Transforming Growth Factor beta - metabolism</topic><topic>Transforming Growth Factor beta1 - metabolism</topic><topic>Transforming Growth Factor beta1 - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>da Silva, Rafael André</creatorcontrib><creatorcontrib>Roda, Vinicius Moraes de Paiva</creatorcontrib><creatorcontrib>Akamine, Priscilla Sayami</creatorcontrib><creatorcontrib>da Silva, Daniela Simões</creatorcontrib><creatorcontrib>Siqueira, Paula Veloso</creatorcontrib><creatorcontrib>Matsuda, Monique</creatorcontrib><creatorcontrib>Hamassaki, Dânia Emi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental eye research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>da Silva, Rafael André</au><au>Roda, Vinicius Moraes de Paiva</au><au>Akamine, Priscilla Sayami</au><au>da Silva, Daniela Simões</au><au>Siqueira, Paula Veloso</au><au>Matsuda, Monique</au><au>Hamassaki, Dânia Emi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells</atitle><jtitle>Experimental eye research</jtitle><addtitle>Exp Eye Res</addtitle><date>2023-01</date><risdate>2023</risdate><volume>226</volume><spage>109336</spage><epage>109336</epage><pages>109336-109336</pages><artnum>109336</artnum><issn>0014-4835</issn><eissn>1096-0007</eissn><abstract>Aging increases the risks for developing fibrocontractile membranes on the retina, which causes significant macular distortion, as in the idiopathic epiretinal membrane (iERM). Retinal Müller glial cells are components of these membranes and may play a key role in the iERM pathogenesis. The transforming growth factor-β (TGF-β) induces Müller cell transdifferentiation into myofibroblast, reducing glial cell markers (glutamine synthetase, GS, and glial fibrillary acidic protein, GFAP) and increasing α-smooth muscle actin (α-SMA). Our aim was to investigate the effect of the TGF-β inhibitor galunisertib (LY2157299) on the glial-mesenchymal transition and contraction of Müller cells.
MIO-M1 human Müller cells were treated with TGF-β1 (10 ng/mL), galunisertib (5, 10 and 20 μM) and TGF-β1+galunisertib for 24h and 48h. Galunisertib cytotoxicity was analyzed by MTT and trypan blue, and TGF-β1 blockade by phospho-SMAD3 immunofluorescence. Caspase-3 (cell death indicator), GS, GFAP and α-SMA expression was examined by immunofluorescence, Western blotting, and qPCR analysis. Cell contractility was determined by collagen gel contraction assay with Müller cells incorporated.
Galunisertib did not show cytotoxicity at the concentrations evaluated and maintained the Müller cells phenotype, ensuring the GS expression. Galunisertib inhibited the TGF-β1 pathway by decreasing phospho-SMAD3 immunoreactivity, attenuated the α-SMA expression, and prevented the contraction of Müller cells in collagen gel.
Although more studies are needed, in vitro assays suggest that galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes and prevent retinal detachment and consequent loss of vision.
•TGF-β signaling induces glial-mesenchymal transition.•Galunisertib inhibits TGF-β-induced glial-mesenchymal transition and Müller cell contraction.•Galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36455675</pmid><doi>10.1016/j.exer.2022.109336</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-4351-6002</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-4835 |
ispartof | Experimental eye research, 2023-01, Vol.226, p.109336-109336, Article 109336 |
issn | 0014-4835 1096-0007 |
language | eng |
recordid | cdi_proquest_miscellaneous_2746391182 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Actins - metabolism Collagen - metabolism Ependymoglial Cells - metabolism Epiretinal Membrane - metabolism Galunisertib Glial-mesenchymal transition Humans Müller cell Neuroglia - metabolism TGF-β Transforming Growth Factor beta - metabolism Transforming Growth Factor beta1 - metabolism Transforming Growth Factor beta1 - pharmacology |
title | Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A53%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blockade%20of%20the%20TGF-%CE%B2%20pathway%20by%20galunisertib%20inhibits%20the%20glial-mesenchymal%20transition%20in%20M%C3%BCller%20glial%20cells&rft.jtitle=Experimental%20eye%20research&rft.au=da%20Silva,%20Rafael%20Andr%C3%A9&rft.date=2023-01&rft.volume=226&rft.spage=109336&rft.epage=109336&rft.pages=109336-109336&rft.artnum=109336&rft.issn=0014-4835&rft.eissn=1096-0007&rft_id=info:doi/10.1016/j.exer.2022.109336&rft_dat=%3Cproquest_cross%3E2746391182%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2746391182&rft_id=info:pmid/36455675&rft_els_id=S0014483522004171&rfr_iscdi=true |